Impact of Dosing on Functional and Clinical Outcomes of Patients With Progressive Pulmonary Fibrosis Treated With Nintedanib: Data From a Real-World, Multicentric, Italian Study
Arch Bronconeumol. 2025 Nov 20:S0300-2896(25)00412-0.
doi: 10.1016/j.arbres.2025.11.005.
Online ahead of print.
[Article in
English,
Spanish]
Authors
Jacopo Cefalo
1
, Francesco Varone
2
, Fabrizio Luppi
3
, Paolo Cameli
4
, Stefania Cerri
5
, Mariangela Valentina Puci
6
, Alessia Martini
2
, Giovanni Franco
3
, Umberto Zanini
3
, Tommaso Pianigiani
4
, Athina Patsoura
5
, Luca Richeldi
2
, Elena Bargagli
4
, Giovanni Sotgiu
6
, Michele Mondoni
7
Affiliations
- 1 Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy. Electronic address: jacopo.cefalo@asst-santipaolocarlo.it.
- 2 Respiratory Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
- 3 Respiratory Unit, Fondazione IRCCS "San Gerardo dei Tintori", Università degli Studi di Milano Bicocca, Monza, Italy.
- 4 Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
- 5 Respiratory Disease Unit, University Hospital of Modena, Modena, Italy.
- 6 Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
- 7 Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy; Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
No abstract available